EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)ÄquivalenzstudieMultizentrische Studie

Efficacy, Immunogenicity, and Safety of Modified mRNA Influenza Vaccine

David Fitz-Patrick, Donald S McVinnie, Lisa A Jackson iD, Graham Crowther, Anita Geevarughese, Kevin D Cannon, Lazaro M Garcia, Yanely Pineiro Puebla, Zhuobiao Yi, Luke Cunliffe, Alok Maniar, Agnieszka M Zareba und 8 weitere

New England Journal of Medicine · 20.11.2025 · 393 (20) · 2001-2011

DOI: 10.1056/nejmoa2416779 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift New England Journal of Medicine, erschienen am 20.11.2025. Verfasst von David Fitz-Patrick und 19 weiteren Autor:innen. Beteiligte Einrichtung: East-West Medical Research Institute, Honolulu. Hauptthemen laut MEDLINE: Immunogenicity, Vaccine, Influenza Vaccines, Influenza, Human, mRNA Vaccines. Die Arbeit wurde bisher 47-mal zitiert (Crossref) und nennt 19 Literaturangaben. Gefördert von: CSRD VA, Pfizer, Pfizer Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunogenicity, VaccineInfluenza VaccinesInfluenza, HumanmRNA VaccinesVaccine EfficacyAdolescentAdultFemaleHumansMaleMiddle AgedYoung AdultAntibodies, ViralHemagglutination Inhibition TestsVaccines, InactivatedVaccines, SyntheticHealthy VolunteersInfluenza A Virus, H1N1 SubtypeInfluenza A Virus, H3N2 SubtypeFever

Substanzen

Antibodies, ViralInfluenza VaccinesmRNA VaccinesVaccines, InactivatedVaccines, Synthetic

Autor:innen und Institutionen

  • East-West Medical Research Institute, Honolulu.
  • Vaccine Research and Development, Pfizer, Marlow, United Kingdom.
  • Kaiser Permanente Washington Health Research Institute, Seattle.
  • Vaccine Research and Development, Pfizer, Pearl River, NY.
  • PMG Research of Wilmington, Wilmington, NC.
  • Entrust Clinical Research, Miami.

ORCID-Profile: Lisa A Jackson

Förderung

  • CSRD VA
  • Pfizer
  • Pfizer Inc

Zitieren

APA

Fitz-Patrick, D., McVinnie, D. S., Jackson, L. A., Crowther, G., Geevarughese, A., Cannon, K. D., Garcia, L. M., Pineiro Puebla, Y., Yi, Z., Cunliffe, L., Maniar, A., Zareba, A. M., Ianos, C. A., Gomme, E., Koury, K., Suphaphiphat Allen, P., Anderson, A. S., Gurtman, A., Lindert, K., & Pfizer C4781004 Trial Investigators (2025). Efficacy, Immunogenicity, and Safety of Modified mRNA Influenza Vaccine. New England Journal of Medicine, 393(20), 2001-2011. https://doi.org/10.1056/nejmoa2416779

Vancouver

Fitz-Patrick D, McVinnie DS, Jackson LA, Crowther G, Geevarughese A, Cannon KD, et al. Efficacy, Immunogenicity, and Safety of Modified mRNA Influenza Vaccine. New England Journal of Medicine. 2025;393(20):2001-2011. doi:10.1056/nejmoa2416779

BibTeX
@article{FitzPatrick2025,
  author = {Fitz-Patrick, David and McVinnie, Donald S and Jackson, Lisa A and Crowther, Graham and Geevarughese, Anita and Cannon, Kevin D and Garcia, Lazaro M and Pineiro Puebla, Yanely and Yi, Zhuobiao and Cunliffe, Luke and Maniar, Alok and Zareba, Agnieszka M and Ianos, Claudia Ana and Gomme, Emily and Koury, Kenneth and Suphaphiphat Allen, Pirada and Anderson, Annaliesa S and Gurtman, Alejandra and Lindert, Kelly and Pfizer C4781004 Trial Investigators, Pfizer C4781004 Trial Investigators},
  title = {Efficacy, Immunogenicity, and Safety of Modified mRNA Influenza Vaccine},
  journal = {New England Journal of Medicine},
  year = {2025},
  volume = {393},
  number = {20},
  pages = {2001--2011},
  doi = {10.1056/nejmoa2416779}
}
Kostenlos starten →